ArticleThe oncologist2022

Correction to: Patient-Reported Outcomes with Selpercatinib Treatment Among Patients with RET-Mutant Medullary Thyroid Cancer in the Phase I/II LIBRETTO-001 Trial.

No numbers read from the abstract.

Not cited yet